Shizuoka, Japan

Masayuki Ohmori



 

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 16(Granted Patents)


Location History:

  • Kanagawa, JP (1982)
  • Shizuoka, JP (2011 - 2015)

Company Filing History:


Years Active: 1982-2015

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Masayuki Ohmori

Introduction

Masayuki Ohmori is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. With a total of four patents to his name, Ohmori's work focuses on innovative compounds that target cancer cells effectively.

Latest Patents

Ohmori's latest patents include an aminopyrazole derivative that presents a method for treating cancer. This method involves administering a pharmaceutically effective amount of a composition containing a compound represented by a specific formula. The formula includes various groups that can be modified to enhance the compound's effectiveness. Another patent involves a compound that can inhibit fibroblast growth factor receptor (FGFR) family kinase in cancer tissues, showcasing his commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Masayuki Ohmori has worked with prominent companies in the pharmaceutical industry. He has been associated with Chugai Seiyaku Kabushiki Kaisha and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to develop and refine his innovative ideas in drug development.

Collaborations

Ohmori has collaborated with talented individuals in his field, including Naoki Taka and Kyoko Takami. These collaborations have likely contributed to the success of his research and the development of his patents.

Conclusion

Masayuki Ohmori's contributions to cancer treatment through his innovative patents highlight his role as a significant inventor in the pharmaceutical industry. His work continues to inspire advancements in medical research and drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…